uniQure Announces Presentations at the Upcoming 13th Annual Congress of the European Association for Haemophilia and Allied D...
February 04 2020 - 7:00AM
uniQure N.V. (NASDAQ: QURE), a leading gene therapy company
advancing transformative therapies for patients with severe medical
needs, today announced that seven presentations, of which one is an
oral presentation, will be delivered at the upcoming congress of
the European Association for Haemophilia and Allied Disorders
(EAHAD), held in The Hague, the Netherlands, February 5 – 7, 2020.
Specific details on uniQure’s presentations at
EAHAD include:
- Title: One Year Data from A Phase 2b Trial Of
AMT-061 (AAV5-Padua hFIX Variant), An Enhanced Vector for Gene
Transfer in Adults with Severe or Moderate-Severe Hemophilia B
(ORAL10)Oral Session Title: Session 6:
SLAMDate and Time: Friday February 7, 8:30 – 10:00
a.m. CET
- Title: Stable FIX Expression and Durable
Reductions in Bleeding and Factor IX Consumption for Up To 4 Years
Following AMT-060 Gene Therapy in Adults with Severe or
Moderate-Severe Hemophilia B (Poster 100)Date and
Time: Wednesday February 5, 6:30 – 7:30 p.m. CET
- Title: Clearance of Vector DNA Following
Systemic Administration of AAV5-hFIX Or AAV5-hFIX Padua In Patients
with Severe or Moderate-Severe Hemophilia B (Poster 89)
Date and Time: Wednesday February 5, 6:30 – 7:30
p.m. CET
- Title: Prevalence and Affinity/Avidity
Assessment of Pre-Existing NABS Against AAV1, 2, 5 And 8 Analyzed
In the Serum Of 300 Healthy Donors (Poster 54)Date and
Time: Wednesday February 5, 6:30 – 7:30 p.m. CET
- Title: Seroprevalence Of Pre-Existing NABS
Against AAV1, 2, 5, 6 And 8 in the South African Hemophilia B
Patient Population (Poster 116)Date and Time:
Wednesday February 5, 6:30 – 7:30 p.m. CET
- Title: Evaluation of A Blood Coagulation
Factor IX Variant That Functions Independently of Factor Viii as An
Alternative Treatment of Hemophilia ADate and
Time: Wednesday February 5, 6:30 – 7:30 p.m. CET
- Title: Gene Therapy for People with
Haemophilia B (PWHB): Development of A Cost-Effectiveness Model
Framework (Poster 154)Date and Time: Wednesday
February 5, 6:30 – 7:30 p.m. CET
About uniQure uniQure is
delivering on the promise of gene therapy – single treatments with
potentially curative results. We are leveraging our modular and
validated technology platform to rapidly advance a pipeline of
proprietary gene therapies to treat patients with hemophilia B,
hemophilia A, Huntington's disease, Fabry disease, spinocerebellar
ataxia Type 3 and other diseases. www.uniQure.com
uniQure Contacts:
FOR INVESTORS: |
|
FOR MEDIA: |
|
|
|
Maria E. Cantor |
Eva M. Mulder |
Tom Malone |
Direct: 339-970-7536 |
Direct: +31 20 240 6103 |
Direct: 339-970-7558 |
Mobile: 617-680-9452 |
Mobile: +31 6 52 33 15 79 |
Mobile:339-223-8541 |
m.cantor@uniQure.com |
e.mulder@uniQure.com |
t.malone@uniQure.com |
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jun 2024 to Jul 2024
uniQure NV (NASDAQ:QURE)
Historical Stock Chart
From Jul 2023 to Jul 2024